玻璃体内地塞米松植入剂治疗眼弓蛔虫病的安全性与有效性
回顾性研究纳入78例眼弓蛔虫病患者,51例接受玻璃体内地塞米松(DEX)植入剂治疗,27例未干预。DEX组玻璃体混浊评分和最佳矫正视力改善优于对照组,玻璃体混浊评分为0的比例随时间升高;两组眼压升高≥10 mmHg及白内障进展无显著差异,对照组更多眼需视网膜手术。
要点
- DEX组玻璃体混浊评分(p=0.001)和最佳矫正视力(p=0.022)优于对照组。
- DEX组玻璃体混浊评分为0的比例在V1、V3、V6分别为67.4%、42.9%、44.9%(p<0.001)。
- 两组眼压升高≥10 mmHg及白内障进展无显著差异,对照组更多眼需视网膜手术(p<0.001)。
核心结论
- 本研究首次探讨玻璃体内DEX植入剂用于眼弓蛔虫病患者,可有效减轻眼部炎症并改善未累及黄斑患者的最佳矫正视力。
研究设计与样本
- 回顾性研究纳入78例眼弓蛔虫病患者,DEX组51例接受玻璃体内DEX植入剂治疗,对照组27例未干预。
主要发现
- 对照组V0至V6玻璃体混浊评分和最佳矫正视力无变化。
- DEX组玻璃体混浊评分为0的比例在V0、V1、V3、V6分别为0%、67.4%、42.9%、44.9%(p<0.001)。
- DEX组平均最佳矫正视力从logMAR 1.5±0.9改善至V1的1.2±0.9、V3的1.4±1.0、V6的1.4±1.2。
- DEX组V1时较好的最佳矫正视力与年龄较大(p=0.038)和黄斑未受累(p=0.000)相关。
- 两组眼压升高≥10 mmHg、白内障进展和形成无显著差异,对照组更多眼需视网膜手术(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate the safety and effectiveness of intravitreal dexamethasone (DEX) implant in patients with active uveitis due to ocular toxocariasis (OT). METHODS: Seventy-eight patients with OT were recruited in this retrospective study, including 51 patients in DEX group treated with intravitreal DEX implant and 27 patients in control group without intervention. The reduction of vitreous haze scores (VHS), the best-corrected visual acuity (BCVA) changes, intraocular pressure (IOP) and cataract progression and formation were recorded at baseline (V0), 1 (V1), 3 (V3) and 6 months (V6) after treatment in DEX group, and V0 and V6 in control group. RESULTS: There was no change in VHS and BCVA in control group between V0 and V6. Better VHS (p=0.001) and BCVA (p=0.022) was achieved in DEX group; the rate of VHS=0 was 0%, 67.4%, 42.9% and 44.9% at V0, V1, V3 and V6, respectively (p<0.001), and the mean BCVA was improved from logMAR 1.5±0.9 to 1.2±0.9 at V1, 1.4±1.0 at V3 and 1.4±1.2 at V6. A favourable BCVA at V1 was associated with older age (p=0.038) and uninvolved macula (p=0.000) in DEX group. No significant difference in IOP elevation ≥10 mm Hg, cataract progression and formation between groups. More eyes needed retinal surgery in control group (p<0.001). CONCLUSIONS: This was the first study to investigate use of intravitreal DEX implant in OT patients, which can efficiently reduce ocular inflammation and improve BCVA in macular uninvolved patients.
引用
- Sun L, Huang L, Li S, et al. Safety and effectiveness of intravitreal dexamethasone implant in patients with ocular toxocariasis. Br J Ophthalmol. 2024. PMID: 36596664. doi:10.1136/bjo-2022-322244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。